Immunoglobulin A nephropathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:34145N02
Who is this for?
Show terms as
5FDA treatments9Active trials41Specialists8Treatment centers5Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Immunoglobulin A nephropathy, also called IgA nephropathy or Berger's disease, is a kidney disease where a protein called IgA — normally part of your immune system — builds up inside the tiny filtering units of the kidneys (called glomeruli). This buildup causes inflammation that slowly damages the kidneys over time. IgA is an antibody your body makes to fight infections, but in this disease, abnormal forms of IgA get trapped in the kidneys and trigger an immune response that harms kidney tissue. Many people with IgA nephropathy notice blood in their urine, especially during or after a cold or throat infection. Some people also have foamy urine from protein leaking out, swelling in the legs or ankles, and high blood pressure. Symptoms can be very mild at first, and some people are only diagnosed after a routine urine test shows abnormalities. Treatment focuses on slowing kidney damage and controlling blood pressure. Medications like ACE inhibitors or ARBs are commonly used to protect the kidneys. In 2023, the FDA approved sparsentan (Filspari) specifically for IgA nephropathy — the first targeted therapy for this disease. Some patients also receive corticosteroids or other immune-suppressing drugs. A small number of patients eventually develop kidney failure and may need dialysis or a kidney transplant. Early diagnosis and treatment give the best chance of preserving kidney function long-term.

Also known as:

Key symptoms:

Blood in the urine (urine looks pink, red, or cola-colored)Foamy or bubbly urine from protein leaking into the urineSwelling in the hands, feet, ankles, or legsHigh blood pressureFlank or back pain around the kidney areaFatigue and low energyFrequent episodes of blood in the urine during or after a cold or throat infectionDecreased urine output in advanced casesHeadaches related to high blood pressureNausea or loss of appetite in later stages when kidney function declines

Clinical phenotype terms (17)— hover any for plain English
IgA deposition in the glomerulusHP:0000794Macroscopic hematuriaHP:0012587Mild proteinuriaHP:0012595Celiac diseaseHP:0002608Increased circulating IgA concentrationHP:0003261CracklesHP:0030830Foamy urineHP:0031504Glomerular crescent formationHP:0033316Nephrotic range proteinuriaHP:0012593
Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Oct 2026Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

Novartis Pharmaceuticals — PHASE3

TrialNOT YET RECRUITING
Mar 2026A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Hinge Bio — PHASE1

TrialRECRUITING
Dec 2025Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Regeneron Pharmaceuticals — PHASE1

TrialRECRUITING
Oct 2025Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study

Radboud University Medical Center — PHASE2, PHASE3

TrialRECRUITING
Aug 2025A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

Shanghai Henlius Biotech — PHASE2

TrialRECRUITING
Jul 2025Study of BHV-1400 in IgA Nephropathy

Biohaven Therapeutics Ltd. — PHASE1

TrialRECRUITING
Jun 2025Study of Ravulizumab in Pediatric Participants With Primary IgAN

Alexion Pharmaceuticals, Inc. — PHASE3

TrialRECRUITING
Feb 2025Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Novartis Pharmaceuticals — PHASE2

TrialRECRUITING
Feb 2025Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Christian Medical College, Vellore, India — PHASE4

TrialRECRUITING
Sep 2024

Filspari: FDA approved

to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

5 available

Vanrafia

atrasentan· Novartis■ Boxed WarningAccelerated Approval

indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g

Tarpeyo

budesonide delayed-release· Calliditas Therapeutics

TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

Voyxact

sibeprenlimab· OtsukaAccelerated Approval

indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression

Filspari

sparsentan· Travere Therapeutics■ Boxed WarningOrphan Drug

to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression

FABHALTA

IPTACOPAN· Novartis Pharmaceuticals Corporation■ Boxed WarningAccelerated Approval

the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g

Clinical Trials

9 recruitingView all trials with filters →
Phase 35 trials
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Phase 3
Actively Recruiting
· Sites: Alabaster, Alabama; Phoenix, Arizona +265 more · Age: 1899 yrs
A Study of Zigakibart in Adults With IgA Nephropathy
Phase 3
Active
· Sites: Birmingham, Alabama; Huntsville, Alabama +198 more · Age: 1899 yrs
Atrasentan in Patients With IgA Nephropathy
Phase 3
Active
PI: Novartis Pharmaceuticals (Novartis Pharmaceuticals) · Sites: Birmingham, Alabama; Alhambra, California +133 more · Age: 1899 yrs
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Phase 3
Actively Recruiting Prior treatment eligible
PI: Clinical Trials (Hoffmann-La Roche) · Sites: Alabaster, Alabama; Birmingham, Alabama +18 more · Age: 1899 yrs
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Phase 3
Actively Recruiting
· Sites: Palo Alto, California; Aurora, Colorado +12 more · Age: 218 yrs
Phase 41 trial
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Phase 4
Actively Recruiting
PI: Jonathan Barratt, PhD, FRCP (University of Leicester) · Sites: Nadiād, Gujarat; Mysuru, Karnataka +10 more · Age: 1865 yrs
Phase 21 trial
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Phase 2
Actively Recruiting
PI: Novartis Pharmaceuticals (Novartis Pharmaceuticals) · Sites: Birmingham, Alabama; Los Angeles, California +14 more · Age: 1899 yrs
Phase 11 trial
Study of BHV-1400 in IgA Nephropathy
Phase 1
Actively Recruiting
· Sites: Farmington, Connecticut; Miami Lakes, Florida +10 more · Age: 1865 yrs

Specialists

Showing 25 of 41View all specialists →
JL
Jicheng Lv
Specialist
PI on 2 active trials
FP
Fangjian Zhou, Professor
Specialist
PI on 2 active trials
TP
Tae-Hyun Yoo, MD, Ph.D
Specialist
PI on 1 active trial
CG
Craig E Gordon
Specialist
1 Immunoglobulin A nephropathy publication
KC
Kirk N Campbell
Specialist
2 Immunoglobulin A nephropathy publications
BC
Bobby Chacko
Specialist
2 Immunoglobulin A nephropathy publications
DK
Dana Kim
Specialist
2 Immunoglobulin A nephropathy publications
PC
Paolo Cravedi
Specialist
2 Immunoglobulin A nephropathy publications
LS
Luis Sanchez-Russo
Specialist
2 Immunoglobulin A nephropathy publications
RC
Rosanna Coppo
Specialist
2 Immunoglobulin A nephropathy publications
IN
Irene L Noronha
Specialist
2 Immunoglobulin A nephropathy publications
HC
H Terence Cook
Specialist
2 Immunoglobulin A nephropathy publications
AR
Arun Rajasekaran
ALBUQUERQUE, NM
Specialist
3 Immunoglobulin A nephropathy publications
MW
Muh Geot Wong
Specialist
3 Immunoglobulin A nephropathy publications
BR
Brad H Rovin
COLUMBUS, OH
Specialist
4 Immunoglobulin A nephropathy publications
EB
Ethan M Balk
NEW HAVEN, CT
Specialist
1 Immunoglobulin A nephropathy publication
FP
Fernando Fervenza, MD, PhD
ROCHESTER, MN
Specialist
PI on 2 active trials
JM
James Spicer, MD
Specialist
PI on 2 active trials
JP
Jan-Stephan F Sanders, MD PhD
Specialist
PI on 3 active trials
LM
Leah Conley, MBA
FARMINGTON HILLS, MI
Specialist
PI on 1 active trial
SP
Sydney CW Tang, MD, PhD
DALLAS, TX
Specialist
PI on 2 active trials
AF
Ancilla W Fernandes
Specialist
2 Immunoglobulin A nephropathy publications
SA
Sarah N Ali
Specialist
2 Immunoglobulin A nephropathy publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

5 resources
Vanrafia(atrasentan)Novartis
Tarpeyo(budesonide delayed-release)Calliditas Therapeutics
Voyxact(sibeprenlimab)Otsuka
Filspari(sparsentan)Travere Therapeutics
FABHALTA(IPTACOPAN)Novartis Pharmaceuticals Corporation

Travel Grants

No travel grants are currently matched to Immunoglobulin A nephropathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Immunoglobulin A nephropathyForum →

No community posts yet. Be the first to share your experience with Immunoglobulin A nephropathy.

Start the conversation →

Latest news about Immunoglobulin A nephropathy

1 articles
NewsFDASep 15, 2025
Filspari Approved for IgA Nephropathy
The FDA approved Filspari (sparsentan), a dual endothelin and angiotensin receptor antagonist, for IgA nephropathy at risk of disease progression.
See all news about Immunoglobulin A nephropathy

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How much kidney function have I already lost, and what is my current eGFR?,Should I start sparsentan or an ACE inhibitor/ARB, and what are the pros and cons for my situation?,How often do I need blood and urine tests, and what numbers should I watch most closely?,What diet changes will help protect my kidneys — how much protein and salt should I eat?,What is my risk of eventually needing dialysis or a kidney transplant based on my biopsy results?,Are there any clinical trials I should consider for newer IgA nephropathy treatments?,Should other family members be tested, and is there a genetic component in my case?

Common questions about Immunoglobulin A nephropathy

What is Immunoglobulin A nephropathy?

Immunoglobulin A nephropathy, also called IgA nephropathy or Berger's disease, is a kidney disease where a protein called IgA — normally part of your immune system — builds up inside the tiny filtering units of the kidneys (called glomeruli). This buildup causes inflammation that slowly damages the kidneys over time. IgA is an antibody your body makes to fight infections, but in this disease, abnormal forms of IgA get trapped in the kidneys and trigger an immune response that harms kidney tissue. Many people with IgA nephropathy notice blood in their urine, especially during or after a cold o

How is Immunoglobulin A nephropathy inherited?

Immunoglobulin A nephropathy follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Immunoglobulin A nephropathy?

Yes — 9 recruiting clinical trials are currently listed for Immunoglobulin A nephropathy on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Immunoglobulin A nephropathy?

25 specialists and care centers treating Immunoglobulin A nephropathy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Immunoglobulin A nephropathy?

2 patient support programs are currently tracked on UniteRare for Immunoglobulin A nephropathy. See the treatments and support programs sections for copay assistance, eligibility, and contact details.